Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.

Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.

Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.

Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.

Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.

Abstract: The present invention relates to the use of staphylokinase for the preparation of a pharmaceutical composition for treating arterial thrombosis, such as e.g. myocardial infarction. It is demonstrated that staphylokinase can be particularly useful as a thrombolytic agent for the lysis of platelet-rich clots. Furthermore it is demonstrated that staphylokinase, unlike streptokinase, does not induce antibody induction upon repeated administration.

Abstract: Plasminogen activators of the tissue-type and plasminogen activators of the urokinase-type appear to have a synergistic action in vivo when administered together as thrombolytic agents. Use in pharmaceutical compositions and in methods for the preparation and use thereof are set forth.

Abstract: A new plasminogen activator which is very similar to the plasminogen activator from blood can be isolated in good amounts from the culture fluid of human melanoma cells.This new plasminogen activator has a strong thrombolytic effect and pharmaceutical compositions thereof may be used in the therapeutic treatment of thrombosis disorders.

Abstract: Novel chemical compounds which are heparin fragments with a molecular weight of from 2,000 to 5,500 covalently bound to antithrombin III, and their use in medicine.

Abstract: A newly isolated constituent of human blood plasma, called antiplasmin, is disclosed together with its isolation method. Further, the invention relates to antiplasmin, a newly isolated constituent of the human blood plasma and to its method of isolation. Further, an antiplasmin-antiserum together with its preparation and utilization, and a method of determining antiplasmin in blood samples are disclosed.

Abstract: A thrombosis test is based on the presence of specific, newly-found, enzyme-inhibitor complexes (such as plasmin-antiplasmin, plasmin-.alpha..sub.2 -macroglobulin, thrombin-antithrombin-III) in blood samples having an activated blood coagulation and/or fibrinolytic system. The test is immunochemical and uses a purified antiserum which has been generated against the enzyme-inhibitor complex. The antiserum is purified by incubating the antiserum with plasminogen and fresh blood plasma and isolating a gamma globulin fraction containing antibodies specific to the enzyme-inhibitor complex. A reagent for the test is prepared by contacting a blood cell suspension or a latex of particles of synthetic resin with the purified antiserum to obtain a suspension or latex in which antibodies from the antiserum are present on the surface of the cells or particles.

Abstract: A test for determining the anti-coagulation level in blood samples is based on ascertaining the presence of heparin-antithrombin-III complex therein. This may be done with the aid of antibodies against thrombin-antithrombin-III complex, such antibodies being used e.g. in the form of a latex reagent or a bloodcell reagent.

Abstract: The invention relates to antiplasmin, a newly isolated constituent of the human blood plasma and to its method of isolation. Further, an antiplasmin-antiserum together with its preparation and utilization, and a method of determining antiplasmin in blood samples are disclosed.

Abstract: Antiserum which has been generated against an enzyme-inhibitor-complex is purified by immunoprecipitating a freshly generated antiserum with fresh human bloodplasma to form a precipitate and a fluid, and subjecting the fluid to chromatographic separation over an insolubilized enzyme-inhibitor complex against which the antiserum has been generated. A reagent for immunochemical assay is prepared by contacting the purified antiserum with red bloodcells or synthetic resin particles to obtain on the surface of the red bloodcells or synthetic resin particles antibodies from the antiserum. In a diagnosis test, blood plasma is contacted with the purified antiserum and with red bloodcells or synthetic resin particles which bear the enzyme-inhibitor complex used to prepare the antiserum, and whether or not agglutination occurs is ascertained.